Ahn-Gook Pharmaceutical

At a glance

Ahn-Gook Pharmaceutical filed 28 disclosures in the last 12 months, including 7 5% holder and 1 m&a. The most recent key filing was on Oct 21: A major holder's stake rose from 48.22% to 48.22%.

Revenue for 2025 was ₩307B, up 13.2% on 2024. Operating margin was 3.2% against 2.5% a year earlier. Debt was 87% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩191B and operating profit of ₩24.7B.

The 2025 annual report lists 424 employees with an average tenure of 4.6 years and average pay of ₩58.6M, #1038 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩430.2M each on average. It paid ₩633 per common share in cash dividends, against ₩440 a year earlier (+43.9%). 어진 and related parties held 48.22% at year end.

Of 1 recent 5%+ holder report, 0 raised and 0 cut a stake; the largest stake reported was 48.22% on Oct 21.

From the 2025 annual report

Staff: 424 (266 men, 158 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩24.9B. Directors and auditors: 5, paid ₩2.2B in total.

Dividends (common shares)

Largest shareholder

어진 holds 43.22%; with 5 related parties the group holds 48.22% of common shares at year end (from 48.45% at the start of the year).

Individuals paid ₩500M or more

Auditor: 대주회계법인 · opinion: Unqualified.

Rankings: Dividend yield #43 of 1,084

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports